Ranibizumab biosimilar (Shanghai United Cell Biotechnology)

雷珠单抗生物类似药（上海联合赛尔生物）

Report date: 2023/06/20 20:00:54

Base Information

Drug NameRanibizumab biosimilar (Shanghai United Cell Biotechnology)

Drug Alias Name雷珠单抗生物仿制药（上海联合赛尔生物）

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragmentBiologics > Biosimilar

Mechanisms of ActionVascular endothelial growth factor A inhibitors

TargetsVascular endothelial growth factor A

Therapy Area/IndicationsMacular EdemaMacular Degeneration

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusIND

Highest Status in ChinaIND

Originator CompaniesShanghai United Cell Biotechnology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesShanghai United Cell Biotechnology Co Ltd

Inactive CompaniesN/A

Active IndicationsMacular Edema

Inactive IndicationsMacular Degeneration

Other Information

ATC CodeS01LA04